Document is current

Article History

Received: 30 May 2025

Accepted: 29 August 2025

First Online: 9 October 2025

Declarations

:

: Boehringer Ingelheim was given the opportunity to review the manuscript for medical and scientific accuracy, as well as intellectual property considerations. All authors meet the criteria for authorship, as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment related to the development of the manuscript. The authors have either received research support from, served as an advisor, consultant, speaker, investigator, participant of steering committees and advisory boards, and/or received honoraria from the following sponsors: Charles W. Lynde: AbbVie, Amgen, Arcutis, Bausch Health, BMS, Boehringer Ingelheim, Demira, Eli Lilly, Galderma, GSK, Janssen, Kyowa, Merck, Novartis, Pfizer, Regeneron, Roche, Sun Pharma, UCB, Valeant. Vimal H. Prajapati: AbbVie, Actelion, Amgen, AnaptysBio, Apogee Therapeutics, Aralez, Arcutis, Arena, Asana, Aspen, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Cipher, Concert, CorEvitas, Dermavant, Dermira, Eli Lilly, Galderma, GSK, Homeocan, Incyte, JAMP Pharma, Janssen, LEO Pharma, Medexus, Meiji Pharma, Nektar Therapeutics, Nimbus Lakshmi, Novartis, Organon, Pediapharm, Pfizer, RAPT Therapeutics, Regeneron, Reistone, Sanofi Genzyme, Sun Pharma, Takeda, Tribute, UCB, Valeant. Melinda J. Gooderham: AbbVie, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Bausch Health, BMS, Boehringer Ingelheim, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, Janssen, Kyowa Kirin, LEO Pharma, MedImmune, Meiji, Merck, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, Tarsus, UCB, Union, Ventyx. H. Chih-ho Hong: AbbVie, Amgen, Arcutis, Avillion, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Celtrion, Cutanea, Dermira, Dermavant, DS Biopharma, Eli Lilly, Evelo Biosciences, Galderma, GSK, Incyte, Janssen, LEO Pharma, MedImmune, Merck, Mirimar, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, UCB. Mark G. Kirchhof: AbbVie, Eli Lilly, Janssen, Novartis, Pfizer, UCB, Sanofi Genzyme. Perla Lansang: Amgen, AbbVie, Eli Lilly, Janssen, LEO Pharma, Novartis, Valeant. Julien Ringuet: AbbVie, Alumis, Amgen, Arcutis, Aristea, ASLAN Therapeutics, Bausch Health, Boehringer Ingelheim, Bristol Myers Squibb, Concert Pharmaceuticals, CorEvitas, Eli Lilly, Galderma, Incyte, Innovaderm, Janssen, La Roche Posay, LEO Pharma, L’Oréal, NKS Health, Novartis, Organon, Pfizer, Sandoz, Sanofi Genzyme, Sun Pharma, UCB. Irina Turchin: AbbVie, Amgen, Arcutis, Bausch Health, BMS, Boehringer Ingelheim, Eli Lilly, Galderma, Incyte, Janssen, LEO Pharma, Mallinckrodt, Novartis, Pfizer, Sanofi, Sun Pharma, UCB. Ron Vender: AbbVie, Actelion, Amgen, Astellas, Dermira, Eli Lilly, Galderma, Janssen Ortho, LEO, Merck, Novartis, Pfizer, Regeneron, Takeda. Jensen Yeung: AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GSK, Janssen, LEO Pharma, MedImmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Takeda, UCB, Valeant, Xenon. Kim A. Papp: AbbVie, Acelyrin, Akros, Alumis, Amgen, Arcutis, Bausch Health/Valeant, Boehringer Ingelheim, Bristol Myers Squibb, Can-Fite Biopharma, Celltrion, Concert Pharmaceuticals, Dermavant, Dermira, DiCE Pharmaceuticals, DiCE Therapeutics, Eli Lilly, Evelo Biosciences, Forbion, Galderma, Horizon Therapeutics, Incyte, Janssen, Kymab, Kyowa Hakko Kirin, LEO Pharma, Meiji Seika Pharma, Mitsubishi Pharma, Nimbus Therapeutics, Novartis, Pfizer, Reistone, Sanofi Genzyme, Sandoz, Sun Pharma, Takeda, Tarsus Pharmaceuticals, UCB Pharma, Zai Lab.

: Ethics approval was not required, as the nature of this work did not involve human or animal subjects. Where tools have been used for the creation of figures/images/tables/other material in the submission, the appropriate licenses/permissions have been obtained to allow publication in this journal and to permit reuse of the article, in whole or in parts, for all purposes, including any commercial reuse.